Response Pharmaceuticals

Response Pharmaceuticals is a private, clinical-stage biotech targeting the significant unmet need for weight management in patients on antipsychotic therapies and those discontinuing GLP-1 agonists. Its lead asset, RDX-002, has generated positive Phase 2 data as a potential long-term option for weight maintenance post-GLP-1 therapy and for antipsychotic-induced weight gain. The company is led by a seasoned team with deep experience in cardiometabolic drug development and is backed by Series A financing. Its strategy positions it in the large and growing obesity/metabolic health market with a differentiated mechanism of action.

Intestinal-specific microsomal triglyceride transfer protein (iMTP) inhibition platform for reducing dietary fat and cholesterol absorption.

In post-GLP-1 maintenance, competition is emerging from other biotechs and large pharma exploring combination and sequential therapies. In AIWG, competition is less direct but includes generic weight-loss drugs and lifestyle interventions; RDX-002's specific mechanism and indication could offer a differentiated profile.